EUVIMEDEUVIMED entdecken
Crossref

Integrin αvβ3–Targeted SLNs for Co-Delivery of Paclitaxel and Quercetin in Triple-Negative Breast Cancer

Mohadeseh Azadi iD, S Mohsen Asghari iD, Tahereh Rahdari, Saeed Azadarmaki, Kaveh Kavousi iD, Ali Akbar Moosavi-Movahedi iD

ACS Applied Materials & Interfaces · 2026

DOI: 10.1021/acsami.5c24911 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Applied Materials & Interfaces, 2026. Verfasst von Mohadeseh Azadi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biochemistry and Biophysics, University of Tehran, Tehran 1417466191, Iran. Hauptthemen laut MEDLINE: Quercetin, Triple Negative Breast Neoplasms, Integrin alphaVbeta3, Paclitaxel. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The pronounced therapeutic recalcitrance of triple-negative breast cancer (TNBC) fundamentally stems from its molecular target paucity and aggressive pathophysiology. Although paclitaxel and quercetin (PTX/Q) have been explored as complementary agents, their concurrent use is limited by poor solubility, rapid systemic clearance, and dose-related toxicities. To address these constraints, we developed a C-peptide-functionalized solid lipid nanoparticle (SLN) system designed to enhance the codelivery of PTX and Q to αvβ3-expressing TNBC cells. The optimized SLN-PTX-Q-pep formulation exhibited a spherical morphology, a mean hydrodynamic diameter of approximately 415 nm, and high encapsulation efficiencies for both PTX (96.9 ± 0.6%) and Q (91.8 ± 1.5%). Thermal analysis and fluorescence spectroscopy confirmed that the drugs were molecularly dispersed within the lipid matrix. The formulation demonstrated excellent blood compatibility, with less than 1.5% hemolysis, and exhibited pH-responsive drug release, with accelerated liberation under mildly acidic, tumor-relevant conditions (pH 5.8). In vitro studies on 4T1 TNBC cells revealed that the targeted nanoformulation achieved a lower PTX IC50 value compared to nontargeted controls. Functional assays confirmed enhanced apoptosis (Annexin V staining), reduced cell migration, and suppression of intracellular reactive oxygen species (ROS). Competitive binding assays verified that the peptide-functionalized SLNs specifically interact with the αvβ3 integrin receptor. In vivo, SPECT imaging demonstrated superior tumor accumulation of the targeted nanoparticles. Correspondingly, mice treated with SLN-PTX-Q-pep showed a significant reduction in tumor growth and lower final tumor burdens, with no signs of systemic toxicity as confirmed by stable body weight, serum biochemistry, and histological analysis of major organs. Collectively, these findings establish that C-peptide-functionalized SLNs are a robust platform for the coordinated delivery of PTX and Q, enhancing tumor-targeted accumulation and therapeutic efficacy in a preclinical TNBC model. This work provides a strong basis for the continued development of dual-drug nanocarriers for difficult-to-treat breast cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

QuercetinTriple Negative Breast NeoplasmsIntegrin alphaVbeta3PaclitaxelNanoparticlesAnimalsFemaleHumansMiceCell Line, TumorApoptosisMice, Inbred BALB CDrug LiberationDrug CarriersLiposomes

Stichwörter der Autor:innen

ROS modulationdual-drug nanocarrierspH-Responsive releasetriple-negative breast cancerαvβ3 integrin targeting

Substanzen

QuercetinIntegrin alphaVbeta3PaclitaxelLipid NanoparticlesDrug CarriersLiposomes

Autor:innen und Institutionen

  • Institute of Biochemistry and Biophysics, University of Tehran, Tehran 1417466191, Iran.
  • Khatam-Ol-Anbia General Hospital, Tehran 1996835911, Iran.

ORCID-Profile: Mohadeseh Azadi, S Mohsen Asghari, Kaveh Kavousi, Ali Akbar Moosavi-Movahedi

Zitieren

APA

Azadi, M., Asghari, S. M., Rahdari, T., Azadarmaki, S., Kavousi, K., & Moosavi-Movahedi, A. A. (2026). Integrin αvβ3–Targeted SLNs for Co-Delivery of Paclitaxel and Quercetin in Triple-Negative Breast Cancer. ACS Applied Materials & Interfaces. https://doi.org/10.1021/acsami.5c24911

Vancouver

Azadi M, Asghari SM, Rahdari T, Azadarmaki S, Kavousi K, Moosavi-Movahedi AA. Integrin αvβ3–Targeted SLNs for Co-Delivery of Paclitaxel and Quercetin in Triple-Negative Breast Cancer. ACS Applied Materials & Interfaces. 2026. doi:10.1021/acsami.5c24911

BibTeX
@article{Azadi2026,
  author = {Azadi, Mohadeseh and Asghari, S Mohsen and Rahdari, Tahereh and Azadarmaki, Saeed and Kavousi, Kaveh and Moosavi-Movahedi, Ali Akbar},
  title = {Integrin αvβ3–Targeted SLNs for Co-Delivery of Paclitaxel and Quercetin in Triple-Negative Breast Cancer},
  journal = {ACS Applied Materials & Interfaces},
  year = {2026},
  doi = {10.1021/acsami.5c24911}
}
Kostenlos starten →